| Dr Erin Watson Massey, MD | |
|
3640 Nw Samaritan Dr Ste 220, Corvallis, OR 97330-3784 | |
| (541) 768-5300 | |
| Not Available |
| Full Name | Dr Erin Watson Massey |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 17 Years |
| Location | 3640 Nw Samaritan Dr Ste 220, Corvallis, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457478620 | NPI | - | NPPES |
| 500688795 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 0101243984 (Virginia) | Secondary |
| 207V00000X | Obstetrics & Gynecology | MD170377 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Regional Medical Center | Corvallis, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Good Samaritan Hospital Corvallis | 1557270725 | 339 |
News Archive
Underuse of effective treatments for mental health disorders is more pronounced among African Americans than non-Hispanic whites.
ABIVAX an innovative biotechnology company targeting the immune system to eliminate viral disease, announced today that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/AIDS, during this week's HIV DART scientific conference in Los Cabos, Mexico.
An analysis of data from 2005 through 2008 of nine metropolitan areas in the U.S. indicates that health care-associated invasive methicillin-resistant Staphylococcus aureus infections decreased among patients with infections that began in the community or in the hospital, according to a study in the August 11 issue of JAMA.
A new actuarial analysis by Oliver Wyman, Inc. finds that average annual medical claims in the new individual market will be 54 percent higher than they are today five years after implementation of healthcare reform under the Patient Protection and Affordable Care Act (PPACA), excluding the impact of medical inflation.
› Verified 3 days ago
| Entity Name | Mid-valley Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689625980 PECOS PAC ID: 2769391523 Enrollment ID: O20031111000297 |
News Archive
Underuse of effective treatments for mental health disorders is more pronounced among African Americans than non-Hispanic whites.
ABIVAX an innovative biotechnology company targeting the immune system to eliminate viral disease, announced today that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/AIDS, during this week's HIV DART scientific conference in Los Cabos, Mexico.
An analysis of data from 2005 through 2008 of nine metropolitan areas in the U.S. indicates that health care-associated invasive methicillin-resistant Staphylococcus aureus infections decreased among patients with infections that began in the community or in the hospital, according to a study in the August 11 issue of JAMA.
A new actuarial analysis by Oliver Wyman, Inc. finds that average annual medical claims in the new individual market will be 54 percent higher than they are today five years after implementation of healthcare reform under the Patient Protection and Affordable Care Act (PPACA), excluding the impact of medical inflation.
› Verified 3 days ago
| Entity Name | Good Samaritan Hospital Corvallis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962453134 PECOS PAC ID: 1557270725 Enrollment ID: O20031125000163 |
News Archive
Underuse of effective treatments for mental health disorders is more pronounced among African Americans than non-Hispanic whites.
ABIVAX an innovative biotechnology company targeting the immune system to eliminate viral disease, announced today that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/AIDS, during this week's HIV DART scientific conference in Los Cabos, Mexico.
An analysis of data from 2005 through 2008 of nine metropolitan areas in the U.S. indicates that health care-associated invasive methicillin-resistant Staphylococcus aureus infections decreased among patients with infections that began in the community or in the hospital, according to a study in the August 11 issue of JAMA.
A new actuarial analysis by Oliver Wyman, Inc. finds that average annual medical claims in the new individual market will be 54 percent higher than they are today five years after implementation of healthcare reform under the Patient Protection and Affordable Care Act (PPACA), excluding the impact of medical inflation.
› Verified 3 days ago
| Entity Name | Samaritan North Lincoln Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306897491 PECOS PAC ID: 7911816301 Enrollment ID: O20040120000329 |
News Archive
Underuse of effective treatments for mental health disorders is more pronounced among African Americans than non-Hispanic whites.
ABIVAX an innovative biotechnology company targeting the immune system to eliminate viral disease, announced today that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/AIDS, during this week's HIV DART scientific conference in Los Cabos, Mexico.
An analysis of data from 2005 through 2008 of nine metropolitan areas in the U.S. indicates that health care-associated invasive methicillin-resistant Staphylococcus aureus infections decreased among patients with infections that began in the community or in the hospital, according to a study in the August 11 issue of JAMA.
A new actuarial analysis by Oliver Wyman, Inc. finds that average annual medical claims in the new individual market will be 54 percent higher than they are today five years after implementation of healthcare reform under the Patient Protection and Affordable Care Act (PPACA), excluding the impact of medical inflation.
› Verified 3 days ago
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174888010 PECOS PAC ID: 2466353529 Enrollment ID: O20040204000304 |
News Archive
Underuse of effective treatments for mental health disorders is more pronounced among African Americans than non-Hispanic whites.
ABIVAX an innovative biotechnology company targeting the immune system to eliminate viral disease, announced today that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/AIDS, during this week's HIV DART scientific conference in Los Cabos, Mexico.
An analysis of data from 2005 through 2008 of nine metropolitan areas in the U.S. indicates that health care-associated invasive methicillin-resistant Staphylococcus aureus infections decreased among patients with infections that began in the community or in the hospital, according to a study in the August 11 issue of JAMA.
A new actuarial analysis by Oliver Wyman, Inc. finds that average annual medical claims in the new individual market will be 54 percent higher than they are today five years after implementation of healthcare reform under the Patient Protection and Affordable Care Act (PPACA), excluding the impact of medical inflation.
› Verified 3 days ago
| Entity Name | Samaritan North Lincoln Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1306897491 PECOS PAC ID: 7911816301 Enrollment ID: O20061104000117 |
News Archive
Underuse of effective treatments for mental health disorders is more pronounced among African Americans than non-Hispanic whites.
ABIVAX an innovative biotechnology company targeting the immune system to eliminate viral disease, announced today that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/AIDS, during this week's HIV DART scientific conference in Los Cabos, Mexico.
An analysis of data from 2005 through 2008 of nine metropolitan areas in the U.S. indicates that health care-associated invasive methicillin-resistant Staphylococcus aureus infections decreased among patients with infections that began in the community or in the hospital, according to a study in the August 11 issue of JAMA.
A new actuarial analysis by Oliver Wyman, Inc. finds that average annual medical claims in the new individual market will be 54 percent higher than they are today five years after implementation of healthcare reform under the Patient Protection and Affordable Care Act (PPACA), excluding the impact of medical inflation.
› Verified 3 days ago
| Entity Name | Mid-valley Healthcare Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1689625980 PECOS PAC ID: 2769391523 Enrollment ID: O20061104000140 |
News Archive
Underuse of effective treatments for mental health disorders is more pronounced among African Americans than non-Hispanic whites.
ABIVAX an innovative biotechnology company targeting the immune system to eliminate viral disease, announced today that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/AIDS, during this week's HIV DART scientific conference in Los Cabos, Mexico.
An analysis of data from 2005 through 2008 of nine metropolitan areas in the U.S. indicates that health care-associated invasive methicillin-resistant Staphylococcus aureus infections decreased among patients with infections that began in the community or in the hospital, according to a study in the August 11 issue of JAMA.
A new actuarial analysis by Oliver Wyman, Inc. finds that average annual medical claims in the new individual market will be 54 percent higher than they are today five years after implementation of healthcare reform under the Patient Protection and Affordable Care Act (PPACA), excluding the impact of medical inflation.
› Verified 3 days ago
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1801847066 PECOS PAC ID: 2466353529 Enrollment ID: O20061104000163 |
News Archive
Underuse of effective treatments for mental health disorders is more pronounced among African Americans than non-Hispanic whites.
ABIVAX an innovative biotechnology company targeting the immune system to eliminate viral disease, announced today that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/AIDS, during this week's HIV DART scientific conference in Los Cabos, Mexico.
An analysis of data from 2005 through 2008 of nine metropolitan areas in the U.S. indicates that health care-associated invasive methicillin-resistant Staphylococcus aureus infections decreased among patients with infections that began in the community or in the hospital, according to a study in the August 11 issue of JAMA.
A new actuarial analysis by Oliver Wyman, Inc. finds that average annual medical claims in the new individual market will be 54 percent higher than they are today five years after implementation of healthcare reform under the Patient Protection and Affordable Care Act (PPACA), excluding the impact of medical inflation.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Erin Watson Massey, MD Po Box 1189, Corvallis, OR 97339-1189 Ph: () - | Dr Erin Watson Massey, MD 3640 Nw Samaritan Dr Ste 220, Corvallis, OR 97330-3784 Ph: (541) 768-5300 |
News Archive
Underuse of effective treatments for mental health disorders is more pronounced among African Americans than non-Hispanic whites.
ABIVAX an innovative biotechnology company targeting the immune system to eliminate viral disease, announced today that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/AIDS, during this week's HIV DART scientific conference in Los Cabos, Mexico.
An analysis of data from 2005 through 2008 of nine metropolitan areas in the U.S. indicates that health care-associated invasive methicillin-resistant Staphylococcus aureus infections decreased among patients with infections that began in the community or in the hospital, according to a study in the August 11 issue of JAMA.
A new actuarial analysis by Oliver Wyman, Inc. finds that average annual medical claims in the new individual market will be 54 percent higher than they are today five years after implementation of healthcare reform under the Patient Protection and Affordable Care Act (PPACA), excluding the impact of medical inflation.
› Verified 3 days ago
Tamme J Davis, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3640 Nw Samaritan Dr Ste 220, Corvallis, OR 97330 Phone: 541-768-5300 | |
Jessica Mitchell, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3640 Nw Samaritan Dr Ste 220, Corvallis, OR 97330 Phone: 541-768-5300 | |
Dr. Cynthia A. Noble, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2298 Nw Kings Blvd, Corvallis, OR 97330 Phone: 541-224-4068 | |
Lesle Solgaard-tarrant, Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 4065 Nw Glen Eden Dr, Corvallis, OR 97330 Phone: 541-758-8068 | |
Dr. Linda K. Fox, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 400 Nw Walnut Blvd Ste 300, Corvallis, OR 97330 Phone: 541-768-4680 | |
Michelle J Curtis, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3680 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-754-1150 | |
Amey Y Lee, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3680 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-754-1150 |